Overview

BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect

Status:
Completed
Trial end date:
2019-02-11
Target enrollment:
Participant gender:
Summary
This single center, double-blind, randomized study with up to 11 treatment groups evaluates the safety and tolerability, pharmacokinetics, relative bioavailability and food effect of single ascending doses of BAY2328065
Phase:
Phase 1
Details
Lead Sponsor:
Bayer